Wisconsin Alumni Research Foundation

Flugen, Inc.

Gabriele Neumann

Yoshihiro Kawaoka

Jihui Ping

Makoto Ozawa

Huihui Kong

Luke D Jasenosky

Pamuk Bilsel

The invention provides a recombinant biologically contained influenza virus that is a PB2 knockout virus, e.g., one that is useful to generate a multivalent vaccine, and methods of making and using that virus.

Influenza viruses with mutant PB2 gene segment as live attenuated vaccines

The invention provides a composition useful to prepare high titer influenza B viruses, e.g., in the absence of helper virus, which includes internal genes from an influenza B virus vaccine strain or isolate, e.g., one that is safe in humans, for instance, one that does not result in significant disease, that confer enhanced growth in cells in culture, such as MDCK cells, or in eggs.

Influenza B virus replication for vaccine development

The invention provides a composition useful to prepare influenza vaccine viruses, e.g., in the absence of helper virus, which includes internal viral segments from an influenza virus vaccine strain or isolate, e.g., one that is safe in humans, for instance, one that does not result in significant disease, and encodes a heterologous antigen.

Recombinant multivalent influenza viruses

Methods of preparing influenza viruses having altered immunodominant epitopes in HA, e.g., having one or more residues in one or more of antigenic sites A-E in HA altered, and viral vectors, e.g., influenza virus VLPs or non-influenza viruses or VLPs thereof expressing or having influenza HAs with altered immunogenicity as a result of altered immunodominant epitopes therein are provided.

Vectors for eliciting immune responses to non-dominant epitopes in the hemagglutinin (HA) protein

An isolated recombinant influenza virus is provided having PA, PB1, PB2, NP, NS, M, NA and HA viral segments, wherein the PB1 viral segment encodes a PB1 with a residue other than isoleucine at position 711 or the M viral segment encodes a M1 with a residue other than methionine at position 128, wherein the recombinant influenza virus has enhanced replication relative to a corresponding influenza virus having a PB1 viral segment that encodes a PB1 with an isoleucine at position 711 or having a M viral segment that encodes a M1 with methionine at position 128, as well as methods of making and using the virus.

Influenza virus replication for vaccine development

Compositions and methods to prepare influenza virus-like particles (VLPs) are provided.

Generation of infectious influenza viruses from virus-like particles

A vector, composition and method to improve influenza virus replication by inhibiting miRNA lec-7C binding to influenza virus mRNA and/or cRNA.

Influenza virus replication by inhibiting microRNA lec7C binding to influenza viral cRNA and mRNA

Influenza viruses with mutant PB2 segment as live attenuated vaccines

The invention provides a composition useful to prepare influenza viruses, e.g., in the absence of helper virus, using vectors which include tandem transcription cassettes containing PolI and/or PolII promoters.

Recombinant influenza vectors with tandem transcription units

The invention provides a composition useful to prepare high titer influenza viruses, e.g., in the absence of helper virus, which includes internal genes from an influenza virus vaccine strain or isolate, e.g., one that is safe in humans, for instance, one that does not result in significant disease, that confer enhanced growth in cells in culture, such as MDCK cells, or in eggs.

Growing community of inventors

Madison, WI, United States of America

Gabriele Neumann